Tags : G1 Therapeutics

PharmaShots Weekly Snapshot (Aug 17 -21 2020)

1. BioMarin Reports NDA Submission to the US FDA for Vosoritide to Treat Children with Achondroplasia Published: Aug 20, 2020 | Tags:  BioMarin, Reports, NDA, Submission, US, FDA, Vosoritide, Children, Achondroplasia 2. Junshi and Impact to Establish Joint Venture for Senaparib (IMP4297) in China Published: Aug 20, 2020 | Tags:  Junshi, Impact, Establish, Joint Venture, […]Read More

G1 Therapeutics Reports the US FDA Acceptance and Priority Review

Shots: The NDA submission is based on three clinical studies in which Trilaciclib was administered prior to chemotherapy treatment in patients with SCLC and has demonstrated robust myelopreservation benefits. The company anticipates the PDUFA date as Feb 15, 2021 G1 is making Trilaciclib available to SCLC patients in the US, who are unable to enter […]Read More

G1 Therapeutics and Boehringer Ingelheim Collaborate to Co-Promote Trilaciclib for

Shots: Boehringer to receive payments to cover start-up expenses and pre-approval initiatives for a successful commercial launch. Additionally, it receives mid-twenties percentage of net sales in the 1st yr. of commercialization, which decreases to a low double-digit/high single-digit percentage in the 2nd and 3rd year respectively G1 will book revenue in the selective territories and […]Read More